hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses

Osteoporosis International

Volumn 1, Issue 3, 1991, Pages 162-170

  Reeve, J ^a   Bradbeer, J N ^a   Arlot, M ^b   Davies, U M ^a   Green, J R ^a   Hampton, L ^a   Edouard, C ^b   Hesp, R ^a   Hulme, P ^a   Ashby, J P ^c   Zanelli, J M ^a   Meunier, P J ^b  

^a MRC Clinical Research Centre   (United Kingdom)

^b UNIVERSITÉ LYON 1   (France)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Hormone replacement therapy; hPTH 1 34 treatment; Osteoporosis

Indexed keywords

PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; BLOOD; DRUG COMBINATION; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; ILIAC BONE; MALE; OSTEOPOROSIS; TREATMENT OUTCOME; URINE;

AGED; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMAN; ILIUM; MALE; MIDDLE AGE; OSTEOPOROSIS; PARATHYROID HORMONES; PEPTIDE FRAGMENTS; TERIPARATIDE; TREATMENT OUTCOME;

EID: 0026167127     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/BF01625448     Document Type: Article

References (28)

1. The anabolic effect of human parathyroid hormone fragment (hPTH 1–34) therapy on trabecular bone in involutional osteoporosis: Report of a multicentre trial
2. The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment (hPTH 1–34)
3. The use of parathyroid hormone plus 1,25 dihydroxyvitamin D to increase trabecular bone in oesteoporotic men and postmenopausal women
4. Human parathyroid peptide treatment of osteoporosis substantially increases spinal trabecular bone
5. Periodic courses of human 1–34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis
6. Increase of vertebral density in osteoporotic patients: Combination-therapy with 1–38 hPTH and cyclic addition of calcitonin nasal spray
7. Biochemical responses to sequential human parathyroid hormone (1–38) and calcitonin in osteoporotic patients
8. Rates of new bone formation in patients with crush fracture osteoporosis
9. The relative merits of various techniques for measuring radiocalcium absorption
10. The assessment of bone formation and bone resorption in osteoporosis: a comparison between tetracycline-based iliac histomorphometry and whole body85Sr kinetics
11. A new method for calculating the accretion rate of bone calcium and some observations on the suitability of strontium-85 as tracer for bone calcium
12. Bone turnover model based on a continuously expanding exchangeable calcium pool
13. The reproducibility of double isotope deconvolution measurements of radiocalcium absorption
14. Bone histomorphometry in osteoporotic states
15. Impaired osteoblast function in osteoporosis. Comparison between calcium balance and dynamic histomorphometry
16. Bone histomorphometry: standardization of nomenclature, symbols and units
17. Estimation of whole body bone resorption rate: a comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis
18. A simple sensitive saturation assay method for the measurement of adenosine 3′5′-cyclic monophosphate
19. An homologous and sensitive radioimmunoassay for the synthetic aminoterminal (1–34) fragment of human parathyroid hormone: application to the clearance of this peptide administered in vivo
20. Sensitive assay for biologically active fragment of human parathyroid hormone
21. Morphologische Untersuchung der Beckenkammspongiosa bei Patienten mit Osteoporose unter einer Kombinationstherapie mit pulsatiler Gabe von Parathormon (1–38 hPTH) und sequentieller Verabreichung von Calcitonin-Nasenspray
22. A new method for calculating the accretion rate of bone calcium and some observations on the suitability of strontium-85 as tracer for bone calcium
23. The circadian rhythm of intact parathyroid hormone (1–84) and nephrogenous cyclic adenosine monophosphate in normal men
24. Effects of one-year treatment with estrogens on bone mass, intestinal calcium absorption, and 25-hydroxyvitamin D-lα-hyd-roxylase reserve in postmenopausal osteoporosis
25. Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanism of action
26. Long-term effect of nandrolone decanoate, lα-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study
27. Transient hypoparathyroidism induced by synthetic hPTH 1–34 treatment
28. Sex steroids in the pathogenesis and formation of osteoporosis